HC Wainwright Lowers Talaris Therapeutics (NASDAQ:TALS) to Neutral

HC Wainwright lowered shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) from a buy rating to a neutral rating in a report published on Monday morning, The Fly reports. Separately, Morgan Stanley reduced their price objective on Talaris Therapeutics from $6.00 to $3.00 and set an equal weight rating for the company in a report […]

Related Keywords

Chicago ,Illinois ,United States ,Suzanne Ildstad ,Talaris Therapeutics Inc ,Commonwealth Equity Services ,Sg Americas Securities ,Morgan Stanley ,Prospera Financial Services Inc ,Chicago Partners Investment Group ,Talaris Therapeutics Company Profile ,Squarepoint Ops ,Talaris Therapeutics ,Get Rating ,Director Suzanne Ildstad ,Partners Investment Group ,Equity Services ,Talaris Therapeutics Daily ,Nasdaq Tals ,Metals ,Medical ,Downgrade ,Hc Wainwright ,